Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Valneva makes and sells travel and infectious disease vaccines, including the world's only approved chikungunya vaccine.
Valneva is a vaccine company. It makes shots that protect people from diseases they might catch while traveling or from outbreaks, and it sells them to governments, health agencies, and travelers. Its business rests on three main products: a chikungunya vaccine called Ixchiq, a Japanese encephalitis vaccine sold as Ixiaro, and a cholera vaccine called Dukoral.
The chikungunya shot is the crown jewel. Chikungunya is a mosquito-borne virus that causes fever and severe joint pain, and before Valneva there was no approved vaccine anywhere. Ixchiq became the first one cleared for use, winning US approval in late 2023 and later nods in Europe and Canada. The vaccine is approved for adults, and Valneva has been working to extend it to adolescents and to widen access. That first-mover status matters because public health agencies and travel clinics often stick with the only option on the shelf.
Valneva also runs a contract manufacturing business, making vaccines for other companies at its sites in Sweden and Scotland, which brings in steadier cash while its own products ramp up. The company's history is one of repeated reinvention: it was built up through acquisitions, spent years developing a whole-virus COVID-19 vaccine that struggled commercially, and then refocused on travel and infectious disease shots. It is headquartered in Saint-Herblain, France, and listed on Nasdaq. Its biggest risk is simple: a small company betting on a handful of vaccines, dependent on how fast governments and travelers actually buy them.
Saved answer 路 last researched 15 Nov 2026